Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in pediatric refractory generalized myasthenia gravis
2016-001384-37Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eculizumab in myasthenia gravis (MG), sponsored by Alexion Pharmaceuticals. Primary endpoint: Change from baseline in QMG total score over time regardless of rescue treatment. Started Dec 2018; status: completed.
02
Drugs
eculizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2016-001384-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001384-37.